Cervical cancer affects more than 400,000 women in the world each year and represents the second most common malignancy found after breast cancer (6). Cervical cancer screening is currently based on the Papanicolaou (Pap) smear, which has had a vast impact on the reduction in the incidence of this disease in developed countries. However, the sensitivities of cytological tests vary greatly according to the experience of the cytologists and the type of quality control in place (4, 12, 14, 21, 29) .
Cervical cancer affects more than 400,000 women in the world each year and represents the second most common malignancy found after breast cancer (6) . Cervical cancer screening is currently based on the Papanicolaou (Pap) smear, which has had a vast impact on the reduction in the incidence of this disease in developed countries. However, the sensitivities of cytological tests vary greatly according to the experience of the cytologists and the type of quality control in place (4, 12, 14, 21, 29) .
Epidemiological and functional studies have clearly demonstrated that certain types of human papillomavirus (HPV) from the genus alpha of the HPV phylogenetic tree, referred to as high-risk (HR) types, are the etiological cause of cervical cancer. A recent survey of 11 case-control studies in nine countries showed that 15 different HPV types are classified as high-risk types, namely, types 16, 18, 31, 33, 35, 39, 45 , 51, 52, 56, 58, 59, 68, 73, and 82. An additional three HPV types of the same genus (types 26, 53, and 66) were classified as probable high-risk types, while several others were considered low-risk types, including HPV type 70 (HPV-70), which is phylogenetically related to the high-risk HPV types (15) . The clinical value of HPV DNA testing has increasingly been recognized (10) .
Independent studies have shown that HPV DNA detection, when it is used as a primary screening method, has a higher sensitivity and a higher negative predictive value for the detection of preinvasive disease than the conventional Pap smear or the liquid-based cytology methods (2, 5, 22) . In fact, in the United States the Food and Drug Administration has authorized the use of a commercial HPV detection test, Hybrid Capture-II (Digene), in women aged 30 years and older for primary screening, in addition to cytology and for the triage of atypical squamous cells of undetermined significance.
Constant progress in HPV typing based on PCR methods has been made over the past few years. The majority of available protocols use degenerate and/or consensus primers, followed by an additional assay that allows the identification of the specific HPV types (7, 18, 25, 27, 30) . Most commonly used PCR assays amplify the L1 region (18, 28) , the E1 region (26) , or the E6 and E7 regions (7, 20) . The use of degenerate and/or consensus primers offers the advantage of detecting a large spectrum of HPV types by a single PCR. However, they may be less efficient in detecting specific HPV types, leading to some underdetection, particularly in cases of multiple infections (3, 16, 17) .
In this report, we describe the development of a reliable novel E7 PCR-based assay for the detection of a large spectrum of high-risk HPV types. The assay combines the advantages of the multiplex PCR methods, i.e., high sensitivity and the possibility to perform multiple amplifications in a single template preparation kits (Roche Applied Science, Mannheim, Germany), according to the recommendations of the manufacturer. The purified amplicons were sequenced with the respective amplification primers on an ABI 3700 automated DNA analysis platform. The identities of the sequences obtained were verified by using Basic Local Alignment Search Tool (BLAST) analysis.
Statistical analyses. Descriptive statistics were carried out for the 92 women (panel 2) tested for HPV detection by the multiplex PCR/APEX (Lyon) and the GP5ϩ/GP6ϩ PCR (Amsterdam) methods. The overall and type-specific percentages of HPV positivity were calculated for infections with single and multiple HPV types. The kappa statistic was calculated to measure the agreement between the overall rate of HPV positivity detected by the two methods beyond that expected by chance. Kappa estimates of less than 0.2 represent "poor" agreement, those between 0.2 and 0.6 indicate that the agreement can be considered from "fair" to "moderate," and kappa values more than 0.6 represent "good" or "very good" agreement (1).
RESULTS

Primer design and development of multiplex-PCR protocol.
We have selected 19 different mucosal HPV types (types 16, 18, 26, 31, 33, 35, 39, 45 , 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, and 82) according to their association with cervical cancers or their phylogenetic link with the high-risk types (15) . After alignment of the E7-region DNA sequences of all selected HPV types, 19 pairs of primers specific for each HPV type were designed at the 3Ј region of this viral gene. The sequences of all forward and reverse primers and the predicted sizes of the PCR products are shown in Table 1 . As a first step, we tested by PCR the functionality of all primer pairs in single reactions using as a template the DNA of the corresponding HPV type. Each pair of primers gave a PCR product of the expected size (data not shown). Next, we tested the efficiencies of the HPV-specific primers in a multiplex PCR. All primers were mixed; and multiplex PCR was performed by using as the template serial dilutions of DNA of three randomly selected HPV types, i.e., types 16, 26 , and 66 (from 1,000 to 0 copies of the viral genome). PCR products were obtained even when only 10 copies of the viral genome for each HPV type were used as template (data not shown). Thus, the presence of a large number of primers in the PCR mixture does not hamper the sensitivity of the assay.
Generation and characterization of an array primer extension assay for detection of the different HPV types. To determine the HPV types after performing a multiplex PCR, we have developed an APEX assay. Two oligonucleotides covering two distinct regions of the E7-region gene were synthesized for the 19 HPV types and were spotted in duplicate on the chip (Table 2 ; Fig. 1C) . APEX combines two different methods, i.e., microarray and Sanger dideoxy sequencing. After PCR, the amplified DNA fragments are hybridized to the chip, which is followed by an extension reaction in the presence of ddNTPs that fluoresce differently when they are labeled. Thus, the HPV type can be confirmed by the position of the positive signal on the chip and the incorporation of the correct florescent Table 2 . Each oligonucleotide has been spotted in duplicate. The four corners contain a mixture of four self-elongating marker oligonucleotides that give signals in all dideoxy nucleotide channels (named N) and one self-elongation marker oligonucleotide that gives a signal only in one dideoxy nucleotide channels (A, G, C, U). Fig. 1 . Together, these data indicate that the multiplex PCR/APEX assay has a high sensitivity and a high specificity for detection of the mucosal high-risk HPV types. Intermethod comparison. To validate further the novel HPV detection assay we blindly analyzed 92 DNA samples extracted from cervical scrapes collected at the Vrije Universiteit Medical Center, which were previously HPV typed by the GP5ϩ/ GP6ϩ PCR/RLB assay (27 Both methods detected similar percentages of HPV-positive samples (63% by multiplex PCR/APEX versus 61% by GP5ϩ/ GP6ϩ PCR/RLB), and the level of concordance between the two assays in identifying HPV-negative or HPV-positive samples was greater than 80% (Table 3 ). In addition, the GP5ϩ/ GP6ϩ PCR detected several low-risk HPV types (e.g., types 6, 11, 42, and 54) which were not included in the multiplex PCR/ APEX assay (data not shown). Multiple infections were detected in 23 women by the multiplex PCR/APEX and in 18 women by the GP5ϩ/GP6ϩ PCR/RLB (Table 3) . Seven women classified as HR HPV negative according to the GP5ϩ/ GP6ϩ PCR/RLB result were found to be positive for infection with a single HR HPV type by the multiplex PCR/APEX assay, while only three women were negative by the multiplex PCR/ APEX assay and positive by the GP5ϩ/GP6ϩ PCR/RLB. Similarly, nine women infected with a single HR HPV type according to the results of GP5ϩ/GP6ϩ PCR/RLB were found to have multiple infections by the multiplex PCR/APEX assay. In contrast, in only two subjects, the multiplex PCR/APEX assay detected infection with a single HPV type that was found to be infection with multiple types by the GP5ϩ/GP6ϩ PCR/ RLB method. Overall, more HPV types were found in multiple infections by our method (n ϭ 71) than by the GP5ϩ/GP6ϩ PCR/RLB assay (n ϭ 47). To evaluate the specificity of our novel assay, we have selected 10 cases in which additional HPV types were detected by multiplex PCR/APEX assay in comparison to the number that were detected by the GP5ϩ/GP6ϩ PCR/RLB method. After PCR, we performed DNA sequencing using HPV type-specific primers. In all cases the DNA sequencing confirmed the data obtained by the multiplex PCR/ APEX assay, excluding the possibility that the higher number of HPV types detected by the novel method was due to unspecific signals (data not shown). As shown in Table 3 , the greatest difference between the two assays in detecting specific HPV types was found for HPV types 16, 33, and 53. More HPV-16-positive infections were identified by the GP5ϩ/ GP6ϩ PCR/RLB assay, while HPV types 33 and 53 were better detected by the multiplex PCR/APEX assay. All five women in whom HPV-33 was detected by multiplex PCR/APEX but not by GP5ϩ/GP6ϩ PCR/RLB were concurrently infected with other HPV types. Figure 2 shows the number of infections with each HPV type detected by both methods or only one method. A small number of infections with HPV types 18, 31, 59, 66, and 68 were detected by multiplex PCR/APEX and not by GP5ϩ/GP6ϩ PCR/RLB, while two infections with HPV-39 were identified only by GP5ϩ/GP6ϩ PCR/RLB. The presence or absence of low-risk HPV types, as determined by the GP5ϩ/GP6ϩ PCR reverse line blot method, did not affect the performance of the multiplex PCR/APEX assay. In fact, it detected similar proportions of high-risk HPV typespecific infections in samples with or without low-risk HPV types. The Fisher exact statistic for testing the differences in the proportions of infections was not significant for the most commonly detected HPV types: HPV-16 (P ϭ 0.56), HPV-18 (P ϭ 0.99), HPV-31 (P ϭ 0.74), HPV-33 (P ϭ 0.33), and HPV-53 (P ϭ 0.55).
DISCUSSION
A considerable number of studies have demonstrated that detection of mucosal HPV DNAs in cervical specimens has significantly contributed to (i) identifying carcinogenic HPV types, (ii) understanding the natural history of the viral infection, and (iii) increasing the sensitivity of the screening for cervical abnormalities. Many accurate methods for HPV detection and typing have been developed in the past few decades (10) . Most of these assays imply the use of degenerated and/or consensus primers that allow the detection of a large spectrum of HPV types with a single PCR. The drawback of this approach is that the various primer sets, although they are generally able to identify with a high sensitivity a broad spectrum of mucosal HPV types, have various efficiencies in detecting multiple infections (3, 16, 17) . Intermethod comparisons clearly showed that the use of only one detection method could easily lead to an underestimation of the overall prevalence of HPV DNAs in clinical specimens (11, 24) . Therefore, the use of more than one assay would be the preferred means for the most reliable assessment of the prevalence of the complete spectrum of relevant HPV types in epidemiological studies.
Here, we describe a novel multiplex PCR-based method with a panel of HPV type-specific primers. This assay detects a wide spectrum of mucosal high-risk HPV types with a high sensitivity by a single PCR and combines the advantages of PCRbased methods that use degenerated/consensus primers and type-specific primers. In addition, in order to identify the HPV types amplified by the multiplex PCR, we have developed a chip assay based on APEX. A comparative analysis between our method and the well-validated PCR-based assay, the GP5ϩ/GP6ϩ PCR, followed by RLB, showed that the multiplex PCR/APEX protocols led to the identification of a higher number of infections with multiple HPV types. In this study, several HPV types were found more frequently by the novel method than by the GP5ϩ/GP6ϩ PCR/RLB assay, especially in women infected with multiple HPV types. These results are in agreement with the idea that in the case of multiple infections, different HPV types will not compete for the same primer set, which is in contrast to case for the GP5ϩ/GP6ϩ PCR method, which uses only one primer set.
The limitation of the current version of our assay is the lower efficiency of detection of HPV-16 than that by the GP5ϩ/ GP6ϩ PCR/RLB protocol. This phenomenon may be explained by possible natural variations within HPV-16 E7-re- gion genes. In fact, a natural variant with a variation in the region selected for the forward PCR primer has been reported (31) . In addition, we are currently investigating whether this apparent reduced sensitivity of the multiplex PCR/APEX method is due to the primers used in the PCR or on the chip. Due to the general features of the multiplex PCR/APEX assay and its high degrees of versatility and flexibility, the sensitivity of the assay for detection of these HPV types can easily be improved by including new or modified oligonucleotides in the multiplex PCR and/or on the chip. Another advantage of our assay is that the PCR amplifies a part of the E7-region gene that is retained in all cancer cells. In contrast, many HPV detection protocols use PCR primers that anneal in the L1 gene, which may be lost or deleted during the integration of the viral DNA in the host genome.
In conclusion, this study describes a novel assay for detection of mucosal high-risk HPV types with a high sensitivity and a high specificity for the detection of several mucosal high-risk HPV types in women infected with single and multiple HPV types. This method may be a very valuable tool for epidemiological studies that aim to determine the distributions of various HPV types in different areas of the world.
